Log in to save to my catalogue

Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a mult...

Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a mult...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_199032388

Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study

About this item

Full title

Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study

Publisher

England: Elsevier Ltd

Journal title

The Lancet (British edition), 2008-10, Vol.372 (9648), p.1463-1472

Language

English

Formats

Publication information

Publisher

England: Elsevier Ltd

More information

Scope and Contents

Contents

Summary Background Oral fumarate (BG00012) might have dual anti-inflammatory and neuroprotective effects. Our aim was to assess the efficacy and safety of BG00012 in patients with relapsing-remitting multiple sclerosis. Methods 257 patients, aged 18–55 years, with relapsing-remitting multiple sclerosis were randomly assigned to receive 120 mg once...

Alternative Titles

Full title

Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_proquest_journals_199032388

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_199032388

Other Identifiers

ISSN

0140-6736

E-ISSN

1474-547X

DOI

10.1016/S0140-6736(08)61619-0

How to access this item